NCT01227278 - A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

421

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

July 31, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

OTHER

Placebo

Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

BIOLOGICAL

Benralizumab 100 mg

Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).

Trial Locations (31)

Unknown

Research Site, Los Angeles

Research Site, Marietta

Research Site, Normal

Research Site, Brooklyn

Research Site, Oklahoma City

Research Site, Greenville

Research Site, Boerne

Research Site, Tyler

Research Site, Richmond

Research Site, Calgary

Research Site, Hamilton

Research Site, Québec

Research Site, Saskatoon

Research Site, Århus C

Research Site, Hellerup

Research Site, København NV

Research Site, Odense C

Research Site, Frankfurt

Research Site, Mainz

Research Site, Gdansk

Research Site, Krakow

Research Site, Lodz

Research Site, Warsaw

Research Site, Barcelona

Research Site, Lleida

Research Site, Málaga

Research Site, Oviedo

Research Site, Cambridge

Research Site, Edinburgh

Research Site, Leicester

Research Site, Manchester